65,437 trials
Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 75.5 percentage of participants
Hereditary Angioedema · HAE
Primary: The Mean Acute Angioedema Attack Rate — 0.675; 0.589; 0.593 Confirmed attacks per week
Coronary Artery Disease · Postoperative Pain · Respiratory Failure
Primary: Pain Scores at Rest Within the First 24 Hours After Extubation — 79.25; 102 Numeric rating score * hours.
Pregnancy Related · Cardiovascular Risk Factor · Obesity
Primary: Change in Systolic Blood Pressure From Baseline (27 Gestational Weeks) to 32 Gestational Weeks — 0.73; -1.56 mmHg
Valve-in-valve Procedures · Aortic Stenosis · Coronary; Obstruction
Primary: ShortCut™ Device- and/or ShortCut™ Procedure-related: Mortality, Stroke — 0 Participants
Biochemical Recurrence of Malignant Neoplasm of Prostate
Primary: Safety and Tolerability — 8; 8; 0; 0 Participants
Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema
Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -1.00; -0.91; -0.95 Points per month
Stage IV Uveal Melanoma
Primary: Clinical Benefit Rate of Previously Treated and Naive Patients — 0; 0; 7; 6 Participants
Prurigo
Primary: WI-NRS4 Response at Week 12 — 20.6; 44.6 percentage of participants — p=0.0003
Substance Use Disorders
Primary: Changes From Baseline Scores Compared to Post-Treatment Scores, Any Positive Youth Urine Drug/Alcohol Screens (Measured at 0, 2, 4, 6, 9, & 12 Months). — 0.68; 0.73…
Community-acquired Pneumonia · Acute Otitis Media · Pharyngitis
Primary: Guideline-concordant Antibiotic Use for Adults With Pharyngitis — 1458; 2477 Participants
COPD Asthma
Primary: Receipt of Recommended Care — 38.2; 23.7 Percentage of guidelines implemented
Immune Thrombocytopenia
Primary: Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall — 44.4; 0.0; 40.0; 40.0 percentage of participants